Oncology Central

ESMO WCGI: Adjuvant FOLFIRINOX new standard of care for pancreatic cancer

Adjuvant FOLFIRINOX chemotherapy has become the standard of care for pancreatic cancer patients following the release of data from the Phase III PRODIGE 24/CCTG PA.6 trial.
Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.




News Headlines

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.